BTIG Reiterates Buy Rating on Haemonetics (HAE)

December 3, 2024 7:38 AM UTC Send to a Friend
BTIG analyst Marie Thibault reiterated a Buy rating and $112.00 price target on Haemonetics (NYSE: HAE).The analyst comments "Earlier this ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login